Table 1.
Clinical Profile of all Type 3 AIP Patients and Subjects in Serial Pancreas Volumetry Cohort
| Characteristics | Type 3 AIP (n = 229) |
Serial pancreas volumetry (n = 48) | |
|---|---|---|---|
| Symptomatica (n = 86) | Asymptomatica (n = 143) | ||
| Median age in years (IQR) | 61 (49–69) | 61 (54–68) | 55 (47–67) |
| Male N (%) | 34 (39.5%) | 66 (46%) | 17 (35%) |
| Cancer type (%) | |||
| Genitourinary | 24 (28%) | 56 (39%) | 19 (40%) |
| Melanoma | 23 (27%) | 28 (20%) | 16 (33%) |
| Other | 39 (45%) | 59 (41%) | 12 (27%) |
| ICI Agent (%) | |||
| CTLA-4 | 8 (9%) | 9 (6%) | 5 (11%) |
| PD-1 | 55 (64%) | 89 (62%) | 28 (58%) |
| Combined | 23 (27%) | 45 (32%) | 15 (31%) |
| ICI doses before elevated lipase (IQR) | 4 (2–6) | 3 (2%–8%) | 5 (2–10) |
| Median days from ICI to type3 AIP (IQR) | 133 (49–329) | 189 (58–366) | 245 (84–435) |
| ICI discontinued (%) | 61 (71%) | 69 (48%) | 27 (56%) |
| Alcohol consumption | 36 (42%) | 66 (46%) | 22 (46%) |
| Smoking history | 48 (56%) | 69 (48%) | 25 (52%) |
| Diabetes before pancreatitis | 14 (16%) | 42 (29%) | 15 (31%) |
| Drug allergy | 53 (62%) | 75 (52%) | 22 (46%) |
| Prior history of pancreatitis | 3 (3.5%) | 3 (2%) | 2 (4%) |
| Abnormal CT on presentation (%) | 15 (17%) | 12 (8%) | 8 (17%) |
AIP, Autoimmune pancreatitis; CTLA-4, cytotoxic T lymphocyte-associated protein 4; IQR, inter quartile range; PD-1, programmed cell death receptor-1; PD-L1, programmed cell death ligand-1.
a
We note no significant differences between symptomatic and asymptomatic group of patients with type 3 AIP.